research Hair transplantation in mice: Challenges and solutions
Researchers successfully transplanted hair follicles in mice, which survived well and helped in wound healing.
Search
for
Sort by
Research
240-270 / 1000+ results 
research Global expression profile and global genome methylation signatures in male patients with androgenetic alopecia
Differences in gene expression and methylation patterns found in AGA patients suggest potential targets for future treatments.
research SULT1A1 (Minoxidil Sulfotransferase) enzyme booster significantly improves response to topical minoxidil for hair regrowth
Enzyme booster SULT1A1 greatly enhances hair regrowth with minoxidil.
research Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
research Male androgenetic alopecia
Hair loss in men treated best with early medication or transplant, new treatments researched.
research The hair shaft: normality, abnormality, and genetics
Hair microscopy is useful for diagnosing hair disorders, but clear definitions are needed for accurate genetic analysis.
research Shedding light on therapeutics in alopecia and their relevance to COVID-19
Some alopecia treatments might help treat COVID-19, but more research is needed.
research α1-AR agonist induced piloerection protects against the development of traction alopecia
Using a certain drug on the skin can help prevent hair loss caused by pulling on the hair.
research Styling without shedding: Novel topical formula reduces hair shedding by contracting the arrector pili muscle
A new topical solution safely reduces hair shedding by 38% on average by tightening a muscle in the scalp.
research Expanding the therapeutic landscape of minoxidil for androgenetic alopecia: topical, oral and sublingual formulations
Minoxidil can treat hair loss with topical, oral, and sublingual options, offering personalized choices.
research The Alopecia Areata Severity and Morbidity Index (ASAMI) Study
Alopecia areata severity is influenced by factors like long disease duration, relapses, treatment response, and mental health, leading to the creation of a new severity measurement tool.
research Telogen Effluvium
Telogen Effluvium is a condition causing excessive hair loss due to stress, illness, drugs, or hormonal changes, and can be treated with specific products or naturally resolves after 3-4 years.
research Sustained hair regrowth with continued ritlecitinib treatment through week 48 in patients with alopecia areata with or without early target responses: Post hoc analysis of the ALLEGRO phase 2b/3 trial
Continued ritlecitinib treatment helps sustain hair regrowth in alopecia areata patients.
research Systemic Treatment of Moderate to Severe Alopecia Areata in Adults: Updated Australian Expert Consensus Statement
New medications could improve treatment for severe alopecia areata in Australia.
research Maintenance, withdrawal, and re-treatment with ritlecitinib and brepocitinib in patients with alopecia areata in a single-blind extension of a phase 2a randomized clinical trial
Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.
research Improvement in Patient‐Reported Emotional Symptoms and Activity Limitations due to Hair Loss in Patients With Alopecia Areata Treated With Ritlecitinib: Additional Analyses From ALLEGRO ‐2b/3
Ritlecitinib improves emotional well-being and activity levels in alopecia areata patients.
research Criteria for Commencing and Continuing Subsidised Janus Kinase Inhibitor Therapy in Australian Alopecia Areata Patients—Results From an Australian Expert Consensus Exercise
Experts created guidelines for who in Australia can get subsidized JAK inhibitor therapy for alopecia areata.
research Long‐term efficacy and safety of baricitinib in patients with severe alopecia areata: 104‐week results from BRAVE‐AA1 and BRAVE‐AA2
Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.
research Med Check
Horizant has risks like other seizure drugs, Johnson & Johnson misled about Risperdal, and Quanterix found a possible link between brain oxygen loss and Alzheimer's markers.
research Treatment of female pattern hair loss with low dose minoxidil.
research Epidermal Wnt/β-catenin signaling regulates adipocyte differentiation via secretion of adipogenic factors
Epidermal Wnt/β-catenin signaling controls fat cell formation and hair growth.
research Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial
Proxalutamide significantly lowered hospital admissions for male COVID-19 patients compared to a placebo.
research Trichodynia and telogen effluvium in COVID-19 patients: Results of an international expert opinion survey on diagnosis and management
COVID-19 patients often experience hair loss and scalp pain, which may be related to the severity of their infection and treatment drugs.
research Patterns of clinical response in patients with alopecia areata treated with ritlecitinib in the ALLEGRO clinical development programme
Ritlecitinib shows promise for treating alopecia areata, especially with early and extended treatment.
research Alopecia areata
research Psychosocial and Occupational Burden on Caregivers of Adolescents With Alopecia Areata in Australia
Caregivers of teens with alopecia areata face significant mental and work-related challenges.
research COLLAB: A Global Survey of Clinical and Laboratory Assessment in Alopecia Areata by Hair Specialists
Hair specialists vary in testing for alopecia areata, highlighting the need for standard guidelines.
research Incidence and prevalence of alopecia areata in the Australian primary care setting: A retrospective analysis of electronic health record data
The analysis found that alopecia areata, a hair loss condition, is not very common in Australia, affecting about 0.13% of people, with new cases most often seen in males aged 19 to 34 years.
research Effect of gender-affirming hormone therapy on hair growth: a systematic review of the literature
Gender-affirming hormone therapy changes hair growth in transgender people, with feminizing therapy reducing hair and masculinizing therapy increasing it, but sometimes additional treatment is needed.
research Female pattern hair loss: current treatment concepts.
Minoxidil 2% and 5% are common treatments for female pattern hair loss, with other options including anti-androgens, oral contraceptives, and hair transplantation.